Evaxion A (EVAX) Non-Current Assets (2019 - 2025)
Evaxion A posted quarterly Non-Current Assets of $3.5 million for Q4 2025, down 5.73% year-on-year from $3.7 million in Q4 2024, and down 17.91% on a QoQ basis from $4.3 million in Q2 2025.
Evaxion A (EVAX) has 7 years of Non-Current Assets data on file, last reported at $3.5 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets fell 5.73% year-over-year to $3.5 million; the trailing twelve-month figure through Dec 2025 stood at $3.5 million (down 5.73% YoY), and the FY2025 full-year result was $3.5 million, down 5.73% from the prior year.
- Non-Current Assets for Q4 2025 stood at $3.5 million, down from $4.3 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $7.8 million in Q3 2021 and bottomed at $2.4 million in Q1 2021.
- The 5-year median for Non-Current Assets is $4.5 million (2023), against an average of $4.8 million.
- The widest annual swing landed in 2021, when Non-Current Assets jumped 437.73%; it then retreated 18.04% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $5.5 million in 2021, then fell by 7.66% to $5.0 million in 2022, then decreased by 9.94% to $4.5 million in 2023, then declined by 18.04% to $3.7 million in 2024, then retreated by 5.73% to $3.5 million in 2025.
- The last three Non-Current Assets figures came in at $3.5 million (Q4 2025), $4.3 million (Q2 2025), and $3.7 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 285.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.51 Mn |
| Jun 30, 2025 | 4.27 Mn |
| Dec 31, 2024 | 3.72 Mn |
| Jun 30, 2024 | 4.53 Mn |
| Dec 31, 2023 | 4.54 Mn |
| Jun 30, 2023 | 5.39 Mn |
| Dec 31, 2022 | 5.04 Mn |
| Jun 30, 2022 | 5.48 Mn |
| Mar 31, 2022 | 5.70 Mn |
| Dec 31, 2021 | 5.46 Mn |
| Sep 30, 2021 | 7.80 Mn |
| Jun 30, 2021 | 4.23 Mn |
| Mar 31, 2021 | 2.43 Mn |
| Dec 31, 2020 | 1.02 Mn |
| Dec 31, 2019 | 126,000.00 |